← Back to headlines
Acumen Provides Update on Drug Development Pipeline and Timelines
Acumen Pharmaceuticals announced its anticipation of a mid-2027 IND filing for its lead EBD candidate and confirmed that topline results for its Phase II ALTITUDE-AD trial are expected in late 2026.
12 Aug, 14:58 — 12 Aug, 14:58
Sources
Showing 1 of 1 sources
